L-Octahydroindole-2-Carboxylic Acid CAS 80875-98-5 Purity >99.0% (HPLC) Perindopril Erbumine Intermediate Factory High Quality

Short Description:

Chemical Name: L-Octahydroindole-2-Carboxylic Acid

CAS: 80875-98-5

Purity: >99.0% (HPLC)

Appearance: White to Off-White Crystalline Powder

Intermediate of Perindopril Erbumine (CAS: 107133-36-8)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name L-Octahydroindole-2-Carboxylic Acid
Synonyms (2S,3aS,7aS)-Octahydroindole-2-Carboxylic Acid; (2S,3aS,7aS)-Octahydro-1H-Indole-2-Carboxylic Acid; Perindopril USP Related Compound A
CAS Number 80875-98-5
CAT Number RF-PI1490
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C9H15NO2
Molecular Weight 169.22
Density 1.135±0.06 g/cm3
Solubility Soluble in Methanol and Water
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Off-White Crystalline Powder
Identification HNMR; HPLC
Purity / Analysis Method >99.0% (HPLC)
Melting Point 256.0~265.0℃
Water (K.F) ≤0.50%
Residue on Ignition ≤0.50%
Specific Rotation [α]D20 -45.0°~-50.0° (C=1, CH3OH)
Total Impurities <1.00%
Heavy Metals (as Pb) ≤20ppm
Test Standard Enterprise Standard
Usage Intermediate of Perindopril Erbumine (CAS: 107133-36-8)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

1

FAQ:

Application:

L-Octahydroindole-2-Carboxylic Acid (CAS: 80875-98-5) is an intermediate in the synthesis of Perindopril (CAS: 82834-16-0) and Perindopril Erbumine (CAS: 107133-36-8). Perindopril Erbumine is a potent and long-acting angiotensin converting enzyme inhibitor, can lower the peripheral vascular resistance with cardiac output and heart rate unchanged. Perindopril shares the indications of ACE inhibitors as a class, including essential hypertension, stable coronary artery disease (reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularization) and treatment of symptomatic heart disease or heart failure. In addition, the Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS) found that perindopril reduces the risk of stroke in both hypertensive and normotensive individuals with a history of stroke or transient ischemic attack.

  • Write your message here and send it to us